MIT Holding, Inc. (MITD) Partnership Commences Treatment of Patients in Phase 3 FDA Clinical Trial With SERRG | Publicwire

MIT Holding, Inc. (OTCQB: MITD) announces the intake of patients for a FDA clinical trial. MITD through its affiliates are acting as sub-investigators for Melinta Theraputics, the primary investigator in the study managed by SERR G Savannah. MIT Holding, Inc. will generate revenues throughout this 12-month study.
http://bit.ly/1vtynzq